Current Research Efforts
AGXV Series - Cholesterol-lowering immunotherapies
Finally, a real solution to high cholesterol
CURRENT STAGE: Lab testing of AGXV1, AGXV2, AGXV3
Our primary focus is our set of immunotherapies designed to permanently enhance cholesterol metabolism through an immune system-mediated removal of inhibitory factors. Our proprietary multitope platform allows for a more targeted immune response to our targets, promising greater LDL and VLDL clearance than competitors. The result will be a permanent increase in LDL clearance, decreasing patients' risk of atherosclerosis and CVD, all while removing the need for expensive, long-term prescriptions to drugs that cause significant, unwanted side effects.
AGXCCV1 - Colon Cancer immunotherapy
CURRENT STAGE: R&D - Prelab development
Utilizing our proprietary multitope platform, AGXCCV1 is designed to enhance the body's immune response to colon cancers. Designed to work in tandem with currently recommended cancer treatment regimens. The result will be improved prognosis and faster remission timelines.